There are many hepatoprotective and enzyme-lowering drugs in the treasury of Chinese medicine and folk herbs in China; several chemical drugs have been extracted or synthesized from them in recent years. In the past, there was a lack of antiviral drugs in China, which played a very important role in the treatment of patients with chronic hepatitis B. These drugs are still the most widely used; they are also expected to be important therapeutic drugs for hepatitis in the future. What are the therapeutic effects of anti-inflammatory and enzyme-lowering drugs? There are many “anti-inflammatory” drugs in traditional Chinese and folk medicine that can lower enzymes and reduce inflammation, and are effective in controlling liver inflammation. In patients with acute exacerbation of the disease, such as serum aminotransferases rising dozens of times, or even jaundice, the most effective is to hang a bottle of glycine or bitter ginseng, which will soon ease the disease. These drugs are not available in Europe and the United States, and we should treasure them. Acute hepatitis B is a self-limiting disease, and anti-inflammatory and enzyme-lowering drugs can moderate the symptoms and stop the progression of the disease. Bifenacoum has been used for more than 20 years and works fast with few adverse effects. Chronic hepatitis B can be temporarily stabilized with these drugs if antiviral therapy is not suitable or available at the moment. For patients with advanced cirrhosis and liver failure, anti-inflammatory and enzyme-lowering and other adjuvant therapies are important treatment measures. Many regions of China are still economically underdeveloped, and patients can hardly afford expensive imported antiviral drugs, which have been used to treat millions of hepatitis patients for decades; currently, most hepatitis patients in China still use only anti-inflammatory and enzyme-lowering drugs to control their symptoms. However, for most patients, anti-inflammatory and enzyme-lowering drugs only provide a temporary reprieve from inflammation and do not help to clear the viral infection, and the lesions will eventually recur. Moreover, the serum transaminases do not accurately reflect the severity of the lesions, and taking “normalization of serum transaminases” as the goal of treating chronic hepatitis B has misled many patients, resulting in some patients progressing to cirrhosis and liver cancer with small fluctuations in transaminases. What is “liver protection”? How to “protect the liver”? The meaning of “hepatoprotective” drugs is not clear, and currently only substances needed in the physiological metabolism of the liver are used as “hepatoprotective” drugs. However, after the drug is absorbed and metabolized, it may not remain the original substance in the body and may not have the same effect. Many patients with chronic hepatitis B have their symptoms alleviated by a combination of measures, and it is not advisable to place too much emphasis on a particular drug. High prices may not necessarily have high effects, and some drugs that have been traditionally applied effectively are generally inexpensive. The credibility of the results of validation by national pharmaceutical organizations is well known, and there are no particularly effective “liver protection” drugs.